VARDENAFIL DIHYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H32N6O4S.2ClH
Molecular Weight	561.525
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.Cl.CCCC1=NC(C)=C2N1N=C(NC2=O)C3=CC(=CC=C3OCC)S(=O)(=O)N4CCN(CC)CC4

InChI

InChIKey=NOIHTGOGFDFCBN-UHFFFAOYSA-N

InChI=1S/C23H32N6O4S.2ClH/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28;;/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30);2*1H

HIDE SMILES / InChI

Molecular Formula	C23H32N6O4S
Molecular Weight	488.603
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB00862
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021400s017lbl.pdf

Vardenafil (Levitra) is an oral therapy for the treatment of erectile dysfunction. It is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide activates the enzyme guanylate cyclase resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum. The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection. The tissue concentration of cGMP is regulated by both the rates of synthesis and degradation via phosphodiesterases (PDEs). The most abundant PDE in the human corpus cavernosum is the cGMPspecific phosphodiesterase type 5 (PDE5); therefore, the inhibition of PDE5 enhances erectile function by increasing the amount of cGMP.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Phosphodiesterase 5A 30 Target ID: CHEMBL1827 Sources: http://www.drugbank.ca/drugs/DB00862	Inhibitor 8297		1.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Erectile dysfunction 35 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021400s017lbl.pdf	Primary		Approved 8429	Levitra Approved Use LEVITRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction. Launch Date 2003

C_max

Value	Dose	Co-administered	Analyte	Population
30.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27318021	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		VARDENAFIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
22.83 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27318021	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		VARDENAFIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.21 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27318021	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		VARDENAFIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
2.4 mg 12 times / day multiple, respiratory (starting) Highest studied dose Dose: 2.4 mg, 12 times / day Route: respiratory Route: multiple Dose: 2.4 mg, 12 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33325799	healthy, 27.5 years (range: 24-31 years) n = 8 Health Status: healthy Age Group: 27.5 years (range: 24-31 years) Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/33325799	Sources: https://pubmed.ncbi.nlm.nih.gov/33325799
120 mg single, oral Highest studied dose Dose: 120 mg Route: oral Route: single Dose: 120 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf	healthy, adult n = 8 Health Status: healthy Age Group: adult Sex: M Population Size: 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf	Other AEs: Back pain, Myalgia... Other AEs: Back pain Myalgia Abnormal vision Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf
2.4 mg single, respiratory Highest studied dose Dose: 2.4 mg Route: respiratory Route: single Dose: 2.4 mg Sources: https://pubmed.ncbi.nlm.nih.gov/33325799	healthy, adult n = 6 Health Status: healthy Age Group: adult Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/33325799	Sources: https://pubmed.ncbi.nlm.nih.gov/33325799
10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34	unhealthy, adult n = 2203 Health Status: unhealthy Age Group: adult Population Size: 2203 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34	Disc. AE: Headache, Flushing... AEs leading to discontinuation/dose reduction: Headache (19 patients) Flushing (10 patients) Rhinitis (5 patients) Tachycardia (4 patients) Nausea (5 patients) Liver function test abnormal (4 patients) Dizziness (3 patients) Hypesthesia (3 patients) Abdominal pain (3 patients) Palpitations (3 patients) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34

AEs

AE	Significance	Dose	Population
Abnormal vision		120 mg single, oral Highest studied dose Dose: 120 mg Route: oral Route: single Dose: 120 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf	healthy, adult n = 8 Health Status: healthy Age Group: adult Sex: M Population Size: 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf
Back pain		120 mg single, oral Highest studied dose Dose: 120 mg Route: oral Route: single Dose: 120 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf	healthy, adult n = 8 Health Status: healthy Age Group: adult Sex: M Population Size: 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf
Myalgia		120 mg single, oral Highest studied dose Dose: 120 mg Route: oral Route: single Dose: 120 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf	healthy, adult n = 8 Health Status: healthy Age Group: adult Sex: M Population Size: 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf
Flushing	10 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34	unhealthy, adult n = 2203 Health Status: unhealthy Age Group: adult Population Size: 2203 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34
Headache	19 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34	unhealthy, adult n = 2203 Health Status: unhealthy Age Group: adult Population Size: 2203 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34
Abdominal pain	3 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34	unhealthy, adult n = 2203 Health Status: unhealthy Age Group: adult Population Size: 2203 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34
Dizziness	3 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34	unhealthy, adult n = 2203 Health Status: unhealthy Age Group: adult Population Size: 2203 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34
Hypesthesia	3 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34	unhealthy, adult n = 2203 Health Status: unhealthy Age Group: adult Population Size: 2203 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34
Palpitations	3 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34	unhealthy, adult n = 2203 Health Status: unhealthy Age Group: adult Population Size: 2203 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34
Liver function test abnormal	4 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34	unhealthy, adult n = 2203 Health Status: unhealthy Age Group: adult Population Size: 2203 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34
Tachycardia	4 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34	unhealthy, adult n = 2203 Health Status: unhealthy Age Group: adult Population Size: 2203 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34
Nausea	5 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34	unhealthy, adult n = 2203 Health Status: unhealthy Age Group: adult Population Size: 2203 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34
Rhinitis	5 patients Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34	unhealthy, adult n = 2203 Health Status: unhealthy Age Group: adult Population Size: 2203 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf Page: p. 34

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inhibitor 1587	substrate 1037 inhibitor 1767	inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2C8 911 CYP2C19 1478	CYP3A5 395 CYP2C8 693 CYP2C19 991 P-gp 1537 BCRP 561 MRP2 205

Drug as perpetrator

Target	Modality	Activity	Metabolite
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	weak [Ki 126 uM]
CYP2C8 965	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	weak [Ki 67.5 uM]
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	weak [Ki 73.2 uM]
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	yes [Ki 1.4 uM]	M-1 6
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	yes [Ki 20.6 uM]	M-4 4
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	yes [Ki 45 uM]	M-1 6
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	yes [Ki 45 uM]	M-1 6
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	yes [Ki 9.8 uM]	M-1 6

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	major	yes (co-administration study) Comment: label: coadministration with ketoconazole (inhibitor) increased mean AUC and Cmax of vardenafil by 10-fold and 4-fold, respectively; coadministration with erythromycin (CYP3A4 substrate) increased mean AUC and Cmax of vardenafil, respectively; coadministration with indinavir (CYP3A4 inhibitor) increased mean AUC and Cmax of vardenafil by 16 fold and 7 fold, respectively; Ritonavir co-administered with vardenafil resulted in a 49-fold increase in vardenafil AUC and a 13 fold increase in vardenafil Cmax; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0
CYP2C19 991	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	minor
CYP2C8 693	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	minor
CYP2C9 1037	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	minor
CYP3A5 395	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=19 Page: 19.0	minor
BCRP 561	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/22775210/ Page: 7.0	yes
MRP2 205	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/22775210/ Page: 7.0	yes
P-gp 1537	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/22775210/ Page: 7.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200179Orig1s000PharmR.pdf#page=17 Page: 17.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:46295	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:46295
MolPort	MolPort-002-672-272	https://www.molport.com/shop/molecule-link/MolPort-002-672-272
ZINC	ZINC000018324776	http://zinc15.docking.org/substances/ZINC000018324776
eMolecules	30390394	https://www.emolecules.com/cgi-bin/more?vid=30390394
eMolecules	36366753	https://www.emolecules.com/cgi-bin/more?vid=36366753
eMolecules	36516854	https://www.emolecules.com/cgi-bin/more?vid=36516854

PubMed

Title	Date	PubMed
Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose.	2001 Aug	11528196
Study shows patients taking vardenafil consistently completed sexual intercourse.	2001 Dec	11998511
Rabbits as models for impotence research.	2001 Jun	11525311
Oral drug therapy for erectile dysfunction.	2001 May	11402584
PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes.	2002	12836729
The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease.	2002 Dec 4	12475462
Pharmacology of phosphodiesterase-5 inhibitors.	2002 Jul-Aug	12166544
[New medications for treatment of erectile dysfunction].	2002 Jun	12166201
Coming together.	2002 Mar	11993447
Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial.	2002 Nov-Dec	12399521
Vardenafil.	2002 Oct	12387708
Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.	2002 Oct 29	12435622
Gateways to Clinical Trials.	2002 Sep	12428432
Erectile dysfunction: oral pharmacotherapy options.	2002 Sep	12358156
Phosphodiesterase 5 inhibitors: current status and potential applications.	2002 Sep	12209148
Vardenafil enhances clitoral and vaginal blood flow responses to pelvic nerve stimulation in female dogs.	2003 Apr	12789394
Hypogonadism and erectile dysfunction: the role for testosterone therapy.	2003 Aug	12934045
Erectile dysfunction in the cardiac patient: how common and should we treat?	2003 Aug	12853773
US advertising campaign begins for alternative to sildenafil.	2003 Aug 30	12946961
Oral drug treatment of erectile dysfunction.	2003 Dec	14695970
Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells.	2003 Jan 1	12393651
New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction.	2003 Jun	12852189
[New treatment options for erectile dysfunction. Pharmacologic and nonpharmacologic options].	2003 Jun	12825147
[Conservative treatment of erectile dysfunction].	2003 Jun 1	12847815
Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003.	2003 Jun 17	12814989
[New PDE-5 inhibitor for treatment of impotence. 9 out of 10 have erections again].	2003 Jun 26	12916343
Pharmacological management of erectile dysfunction.	2003 Mar	12603396
Gateways to clinical trials.	2003 May	12808477
Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference.	2003 Nov	14693300
Overview of phosphodiesterase 5 inhibition in erectile dysfunction.	2003 Nov 6	14609619
[Drug therapy of erectile dysfunction--the current status].	2003 Oct	14569380
Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy.	2003 Oct	14501741
Novel PDE5 inhibitors for the treatment of male erectile dysfunction.	2003 Oct-Nov	14656408
[Medication of the month. Vardenafil (Levitra)].	2003 Sep	14626653
Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups.	2003 Sep	12946758
Phosphodiesterase 5 inhibitors in male sexual dysfunction.	2003 Sep	12917517
FDA approves new drug for treatment of erectile dysfunction in men.	2003 Sep-Oct	14666896
[Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction].	2004 Apr	15148932
Tadalafil and vardenafil.	2004 Apr	15124623
Role of the cardiologist: clinical aspects of managing erectile dysfunction.	2004 Apr	15115189
Pills for erectile dysfunction: now there are three.	2004 Apr	15100064
Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.	2004 Feb	14871543
Vardenafil treatment for erectile dysfunction.	2004 Jan	14742800
Are they better than Viagra? Two new drugs for erectile dysfunction work like Viagra and carry similar risks and benefits. Their subtle differences, however, may make a difference for some men.	2004 Jan	14734283
Therapy of ED: PDE-5 Inhibitors.	2004 Mar-Apr	15146092
Emerging oral drugs for erectile dysfunction.	2004 May	15155143

Patents

Sample Use Guides

In Vivo Use Guide

For most patients, the starting dose is 10 mg, up to once daily. Increase to 20 mg or decrease to 5 mg based on efficacy/tolerability. A starting dose of 5 mg LEVITRA should be considered in patients ≥ 65 years of age. LEVITRA is taken orally, approximately 60 minutes before sexual activity. The maximum recommended dosing frequency is one tablet per day.

Route of Administration: Oral

In Vitro Use Guide

Treatment with vardenafil at concentrations of 50, 100, and 250 umol/L increased expression of PlGF in a dose-dependent manner in human umbilical vein endothelial cells.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:51:38 GMT 2023` Edited by `admin` on `Fri Dec 15 15:51:38 GMT 2023`
Record UNII	5O8R96XMH7
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VARDENAFIL DIHYDROCHLORIDE

Official Name

English

NSC-759103

Code

English

Imidazo[5,1-f][1,2,4]triazin-4(1H)-one, 2-[2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]phenyl]-5-methyl-7-propyl-, hydrochloride (1:2)

Systematic Name

English

VARDENAFIL DIHYDROCHLORIDE [USAN]

Common Name

English

Piperazine, 1-[[3-(1,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxyphenyl]sulfonyl]-4-ethyl-, dihydrochloride

Systematic Name

English

Vardenafil dihydrochloride [WHO-DD]

Common Name

English

VARDENAFIL DIHYDROCHLORIDE [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2127